Kura Oncology (KURA) Net Income towards Common Stockholders (2010 - 2026)
Kura Oncology (KURA) reported Net Income towards Common Stockholders of -$73.3 million for Q1 2026, down 27.69% year-over-year from -$101.4 million in Q1 2025, and down 137.16% quarter-over-quarter from $197.4 million in Q4 2025.
Kura Oncology (KURA) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Kura Oncology (KURA) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$73.3 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$73.3 million, down 27.69% year-over-year; the trailing twelve-month figure through Mar 2026 was -$16.2 million (up 90.99% YoY), and the FY2025 annual result was -$297000.0, up 99.83% from the prior year.
- Net Income towards Common Stockholders retreated to -$73.3 million in Q1 2026 per KURA's latest filing, from $197.4 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $197.4 million in Q4 2025 and troughed at -$74.1 million in Q3 2025.
- A 3-year average of -$27.3 million and a median of -$54.4 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- On a YoY basis, Net Income towards Common Stockholders climbed as much as 1247.57% in 2025 and fell as far as 36.23% in 2025.
- A 3-year view of Net Income towards Common Stockholders shows it stood at -$17.2 million in 2024, then soared by 1247.57% to $197.4 million in 2025, then tumbled by 137.16% to -$73.3 million in 2026.
- Business Quant data shows KURA's Net Income towards Common Stockholders at -$73.3 million in Q1 2026, $197.4 million in Q4 2025, and -$74.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Kura Oncology | 883.44 Mn | 883.44 Mn | 18.00 Mn | -73.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -73.33 Mn |
| Dec 31, 2025 | 197.37 Mn |
| Sep 30, 2025 | -74.12 Mn |
| Jun 30, 2025 | -66.12 Mn |
| Mar 31, 2025 | -57.43 Mn |
| Dec 31, 2024 | -17.20 Mn |
| Sep 30, 2024 | -54.40 Mn |
| Jun 30, 2024 | -50.84 Mn |
| Mar 31, 2024 | -49.53 Mn |
| Dec 31, 2014 | -46,762.00 |
| Sep 30, 2014 | -6,428.00 |
| Jun 30, 2014 | -6,887.00 |
| Mar 31, 2014 | -5,766.00 |
| Dec 31, 2013 | -9,750.00 |
| Sep 30, 2013 | -6,139.00 |
| Jun 30, 2013 | -6,749.00 |
| Mar 31, 2013 | -5,973.00 |
| Dec 31, 2012 | -9,662.00 |
| Sep 30, 2012 | -6,013.00 |
| Jun 30, 2012 | -6,268.00 |